CHARGE syndrome is a rare genetic disorder characterized by a distinctive pattern of congenital anomalies and associated neurodevelopmental challenges. The name CHARGE is an acronym for the classic features: Coloboma, Heart defects, Atresia choanae, Growth retardation, Ear abnormalities, and Genital abnormalities. While primarily considered a neurodevelopmental disorder, recent research has revealed important connections to neurodegenerative processes through epigenetic dysregulation mechanisms.
Overview
CHARGE syndrome is a genetic disorder affecting multiple systems is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research. The syndrome has an estimated prevalence of approximately 1 in 8,500 to 1 in 15,000 live births, making it one of the rarer genetic syndromes involving the nervous system. [@national2023]
Genetics
CHARGE syndrome is primarily caused by heterozygous mutations in the CHD7 gene (Chromodomain Helicase DNA Binding Protein 7), which follows an autosomal dominant inheritance pattern. [@vissers2004] Approximately two-thirds of individuals with CHARGE syndrome have a detectable pathogenic variant in CHD7. [@bergman2011]
Primary Gene
...
CHARGE Syndrome
CHARGE syndrome is a rare genetic disorder characterized by a distinctive pattern of congenital anomalies and associated neurodevelopmental challenges. The name CHARGE is an acronym for the classic features: Coloboma, Heart defects, Atresia choanae, Growth retardation, Ear abnormalities, and Genital abnormalities. While primarily considered a neurodevelopmental disorder, recent research has revealed important connections to neurodegenerative processes through epigenetic dysregulation mechanisms.
Overview
CHARGE syndrome is a genetic disorder affecting multiple systems is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research. The syndrome has an estimated prevalence of approximately 1 in 8,500 to 1 in 15,000 live births, making it one of the rarer genetic syndromes involving the nervous system. [@national2023]
Genetics
CHARGE syndrome is primarily caused by heterozygous mutations in the CHD7 gene (Chromodomain Helicase DNA Binding Protein 7), which follows an autosomal dominant inheritance pattern. [@vissers2004] Approximately two-thirds of individuals with CHARGE syndrome have a detectable pathogenic variant in CHD7. [@bergman2011]
Primary Gene
CHD7 mutations (autosomal dominant) — see CHD7 Gene and CHD7 Protein
CHD7 encodes a chromodomain-containing ATP-dependent chromatin remodeler essential for embryonic development
The protein belongs to the CHD family of chromatin regulators — see also CHD4 Gene, CHD5 Gene
Associated Genes
SEMA3E (Semaphorin 3E) and other semaphorin family members — see SEMA3A Gene, SEMA3F Gene
Rare: Plexin signaling pathway involvement — see Semaphorin/Plexin Signaling Pathway
Epigenetic Mechanisms
CHD7 is a key epigenetic regulator, and its dysfunction contributes to broader neurodegeneration pathways — see Epigenetic Dysregulation Pathway and Epigenetics in Neurodegeneration.
Clinical Features
The hallmark features of CHARGE syndrome include: [@charge2024]
Coloboma — congenital eye defect affecting the iris, retina, or optic nerve
Heart defects — including conotruncal anomalies and septal defects
Atresia choanae — congenital blockage of the nasal passages
Growth retardation — both prenatal and postnatal
Ear abnormalities — including malformed outer ears and hearing loss
CHARGE syndrome involves significant neurodevelopmental manifestations that persist into adulthood: [@hartshorne2022]
Developmental Profile
Developmental delays (motor, language, cognitive)
Autism spectrum features and social communication challenges
Hypothalamic dysfunction affecting circadian rhythms and sleep
Intellectual disability ranging from mild to severe
Sensory processing differences
Neural Circuitry Affected
The neurodevelopmental features of CHARGE syndrome involve disruption of key brain regions and systems:
Cerebral Cortex — cortical development abnormalities
Cerebellum — motor coordination and cognitive functions
Basal Ganglia — movement and habit learning
Hypothalamus — endocrine and autonomic regulation
Adult Neurodegeneration Risk
Emerging evidence suggests that individuals with CHARGE syndrome may have increased susceptibility to neurodegenerative processes later in life due to: [@srivastava2024]
Epigenetic dysregulation — CHD7 mutations disrupt chromatin remodeling essential for neuronal health
DNA damage repair impairment — see DNA Damage and Repair in Neurodegeneration
Oxidative stress vulnerability — see Oxidative Stress in Neurodegeneration
Lysosomal dysfunction — potential intersection with Lysosomal Dysfunction in Neurodegeneration
Molecular Mechanisms
Mermaid diagram (expand to render)
CHD7 Function
CHD7 is a member of the chromodomain helicase DNA-binding (CHD) family of proteins that utilize ATP to remodel chromatin structure. [@kadoch2023] Key functions include:
Chromatin remodeling — regulating nucleosome positioning to control gene accessibility
Transcriptional regulation — recruiting transcriptional complexes to specific genomic loci
Embryonic patterning — critical for development of neural crest cells and cranial structures
Neural stem cell maintenance — supporting proliferation and differentiation of neural progenitors
Treatment and Management
Management of CHARGE syndrome requires a multidisciplinary approach: [@legendre2024]
Surgical interventions — for coloboma, heart defects, and choanal atresia
Hearing rehabilitation — including hearing aids and cochlear implantation
Developmental therapies — occupational, physical, and speech therapy
Endocrine management — hormone replacement for hypogonadism
Monitoring for neurodegeneration — longitudinal assessment of cognitive function in adults
See Immunotherapy for Neurodegenerative Diseases for emerging therapeutic approaches.
Research Connections
Epigenetic Therapies
Understanding CHD7 function provides insights into broader Epigenetic Therapies for Neurodegeneration. Chromatin remodelers represent potential therapeutic targets for: [@fischer2024]
Alzheimer's Disease — see Epigenetic Mechanisms in Alzheimer's Disease
Parkinson's Disease — see Epigenetics in Parkinson's Disease